Gary J. Sharman
YOU?
Author Swipe
View article: Amyloid binding and beyond: a new approach for Alzheimer's disease drug discovery targeting Aβo–PrP<sup>C</sup>binding and downstream pathways
Amyloid binding and beyond: a new approach for Alzheimer's disease drug discovery targeting Aβo–PrP<sup>C</sup>binding and downstream pathways Open
A new approach combining virtual screening,19F and STD NMR, and biochemical assays using hiPSC and targetting multiple pathways involving Aβ, PrPCand Tau provides a more effective strategy for Alzheimer's disease drug discovery than Aβ onl…
View article: Quantitative propagation of assembled human Tau from Alzheimer's disease brain in microfluidic neuronal cultures
Quantitative propagation of assembled human Tau from Alzheimer's disease brain in microfluidic neuronal cultures Open
Tau aggregation and hyperphosphorylation is a key neuropathological hallmark of Alzheimer's disease (AD), and the temporospatial spread of Tau observed during clinical manifestation suggests that Tau pathology may spread along the axonal n…
View article: A KNIME Workflow for Automated Structure Verification
A KNIME Workflow for Automated Structure Verification Open
Adequate characterization of chemical entities made for biological screening in the drug discovery context is critical. Incorrectly characterized structures lead to mistakes in the interpretation of structure-activity relationships and con…
View article: <em>GalNAc</em> mimetics: from synthesis to potential inhibitors in Alzheimer’s Disease
<em>GalNAc</em> mimetics: from synthesis to potential inhibitors in Alzheimer’s Disease Open
N-acetylgalactosamine(GalNAc) belongs to the group of 2-amino-2-deoxysugars which are found in a wide range of biological structures playing a role in in cell-cell interaction and receptor induced cell signaling, among other biological pro…
View article: Discovery of <i>N</i>-methylpiperazinyl flavones as a novel class of compounds with therapeutic potential against Alzheimer’s disease: synthesis, binding affinity towards amyloid β oligomers (Aβo) and ability to disrupt Aβo-PrP<sup>C</sup> interactions
Discovery of <i>N</i>-methylpiperazinyl flavones as a novel class of compounds with therapeutic potential against Alzheimer’s disease: synthesis, binding affinity towards amyloid β oligomers (Aβo) and ability to disrupt Aβo-PrP<sup>C</sup> interactions Open
With no currently available disease-modifying drugs, Alzheimer’s disease is the most common type of dementia affecting over 47 million people worldwide. In light of the most recent discoveries placing the cellular prion protein (PrP C ) as…